GNE-490 is primarily utilized in the field of medical research, particularly in the study and development of treatments for metabolic disorders. It functions as a potent and selective inhibitor of diacylglycerol acyltransferase 1 (DGAT1), an enzyme involved in triglyceride synthesis. By inhibiting DGAT1, GNE-490 has shown potential in reducing fat absorption and improving metabolic parameters, making it a candidate for addressing conditions such as obesity, type 2 diabetes, and related metabolic syndromes. Its application extends to preclinical studies where it is used to explore the mechanisms of lipid metabolism and evaluate therapeutic efficacy in animal models. Additionally, it serves as a valuable tool in understanding the role of DGAT1 in various physiological and pathological processes.